A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Number of Participants With Marked Laboratory Abnormalities

Participants with marked laboratory abnormalities were reported. Marked abnormality criteria: Serum glutamic oxaloacetic transaminase (SGOT); high \>25 units per litre (U/L), albumin (low \< 31 grams per litre \[g/L\]), total protein (\< 60 g/L), phosphate (high \>1.45 millimoles per litre \[mmol/L\]); Low \<0.84 mmol/L), potassium (high \>5 mmol/L; Low \<3.5 mmol/L), platelets (low:\<150×10\^9/L), White blood cells (\[WBCs\]); high: 10.8×10\^9/L and Low:4.3×10\^9/L), basophils (high:\>0.15×10\^9/L), eosinophils (high:\>0.70×10\^9/L), lymphocytes (low:\<1.50×10\^9/L), and neutrophils (low:\<1.83×10\^9/L).

Time frame: Up to Week 126

Number of Participants With Any Adverse Events, Any Serious Adverse Events, And Deaths

An Adverse Events (AEs) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Events (SAEs) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes. The study design tested 3 different starting dose conversion factors at 3 different dosing schedules during the core study period. As study drug doses can be modified continually over time all results for the two long term safety periods were displayed by dose schedule group only.

Time frame: Up to Week 126